Akums Drugs and Pharmaceuticals Ltd has formally submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report, prepared by M/s. SPG & Associates, provides an overview of the company’s adherence to statutory obligations and governance standards during the review period. The documentation confirms the company’s overall commitment to regulatory frameworks and includes detailed annexures regarding the firm’s compliance status.
Annual Governance Review Summary
The company has completed its comprehensive secretarial audit for the fiscal year ending March 31, 2026. This annual review process ensures that all internal practices remain aligned with statutory requirements and corporate governance best practices. The audit was conducted by M/s. SPG & Associates, who verified corporate records, regulatory filings, and disclosure documentation to provide an independent assessment of compliance activities.
Compliance Performance Highlights
The review confirms that the company largely adhered to the mandatory regulatory framework throughout the 2025-26 financial year. The audit process validated several key areas, including:
- Board Governance: Proper functioning and evaluation of the Board and its committees.
- Disclosure Standards: Consistent adherence to the timely release of material information.
- Policy Implementation: Continued alignment of internal corporate policies with updated statutory guidelines.
- Director Standards: Confirmation that all directors meet the required eligibility criteria and are not disqualified under current laws.
Regulatory Observations
While the company demonstrated broad compliance across its operational functions, the audit noted one instance of non-compliance regarding Regulation 17(1)(b). This resulted in a financial penalty of ₹5.95 lakh imposed by the stock exchange. The company has since taken corrective measures and ensured that all previous observations have been addressed, reinforcing its commitment to maintaining the highest standards of corporate transparency moving forward.
Source: BSE
